NCT02535286View on ClinicalTrials.gov

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 18, 2015

Primary Completion Date

November 4, 2021

Study Completion Date

November 4, 2021

Conditions
Chronic Lymphocytic LeukemiaRichter Syndrome
Interventions
DRUG

Umbralisib

A once daily oral agent

BIOLOGICAL

ublituximab

IV anti-CD20 monoclonal antibody

BIOLOGICAL

TG-1501

IV immunotherapy for cancer

Trial Locations (4)

10065

TG Therapeutics Investigational Trial Site, New York

19104

TG Therapeutics Investigational Trial Site, Philadelphia

27710

TG Therapeutics Investigational Trial Site, Durham

98109

TG Therapeutics Investigational Trial Site, Seattle

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

TG Therapeutics, Inc.

INDUSTRY

NCT02535286 - Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation | Biotech Hunter | Biotech Hunter